List of Kimyrsa drug patents

Kimyrsa is owned by Melinta Therap.

Kimyrsa contains Oritavancin Diphosphate.

Kimyrsa has a total of 3 drug patents out of which 0 drug patents have expired.

Kimyrsa was authorised for market use on 12 March, 2021.

Kimyrsa is available in powder;intravenous dosage forms.

Kimyrsa can be used as treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent.

Drug patent challenges can be filed against Kimyrsa from August, 2023.

The generics of Kimyrsa are possible to be released after 16 July, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9649352 MELINTA THERAP High purity oritavancin and method of producing same
Jul, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420592 MELINTA THERAP Methods of treatment using single doses of oritavancin
Aug, 2029

(6 years from now)

US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 12, 2024
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 12 March, 2021

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in